Elevance Health reaffirms 2026 guidance: adjusted EPS ≥$26.75, benefit expense ratio 90.2%±50bps

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

• high

  Reaffirmed full-year 2026 adjusted EPS guidance of at least $26.75 per share (reported EPS at least $19.85 including ~$6.90 of net unfavorable items)

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Reaffirmed benefit expense ratio guidance of 90.2% ±50 bps (range: 89.7%–90.7%), a key medical cost profitability metric

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →